Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Evolva Holding SA
  6. News
  7. Summary
    EVE   CH0021218067

EVOLVA HOLDING SA

(EVE)
  Report
Delayed Quote. Delayed Swiss Exchange - 10/22 11:31:53 am
0.137 CHF   -0.72%
09/27EVOLVA : Issues 40 Million New Shares
MT
09/27Evolva issued 40'000'000 shares out of authorized capital
DJ
09/10EVOLVA : HY 2021 Results Presentation (EN)
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

EQS-Adhoc : Evolva secures additional funding for future growth

05/17/2021 | 01:03am EDT
EQS Group-Ad-hoc: Evolva Holding SA / Key word(s): Miscellaneous 
Evolva secures additional funding for future growth 
17-May-2021 / 07:01 CET/CEST 
Release of an ad hoc announcement pursuant to Art. 53 KR 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Reinach, May 17, 2021 - Evolva (SIX:EVE), the Swiss biotech company focused on the research, development and 
commercialization of products based on nature, today signed an agreement with Nice & Green, a Swiss investment firm, to 
secure additional funding. 
The major activities to be funded include the expansion and diversification of manufacturing capacities in the contract 
manufacturer network as well as investments into commercial activities to sustain high growth in Health Ingredients and 
to build the Health Protection business. For these purposes, the investment facility may be drawn in tranches depending 
on Evolva's operational needs. 
«The additional funding provided by Nice & Green allows us to establish major building blocks on our way to become 
EBITDA positive by 2023», said Oliver Walker, CEO of Evolva. 
Under the agreement, Nice & Green has committed to an additional incremental investment in form of convertible notes 
according to agreed conditions up to a maximum principal amount of CHF 20 million until the end of 2022. The principal 
amount of each convertible note is, at Evolva's discretion, either repayable by way of conversion into ordinary shares 
of the company, or in cash. The conversion price is 95 percent of the lowest daily volume weighted average price for a 
share on the SIX Swiss Exchange during the 6 trading days immediately preceding the conversion. 
About Evolva 
Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on 
nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva's 
employees, half of which are women, are dedicated to make the best products that can contribute to health, wellbeing 
and sensory enjoyment. Find out more at evolva.com. 
For Evolva multimedia content, please visit: evolva.com/multimedia-library. 
Disclaimer 
This press release contains specific forward-looking statements, e.g. statements including terms like believe assume, 
expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties 
and other factors which may result in a substantial divergence between the actual results, financial situation, 
development or performance of the company and those explicity or implicity presumed in these statements. The company 
assumes no responsibility to update forward-looking statements or to adapt them to future events or developments. 
Contact 
Barbara Duci 
Head of Investor and Corporate Relations 
+41 61 485 2003 
+41 79 739 2636 
barbarad@evolva.com 
=---------------------------------------------------------------------------------------------------------------------- 
End of ad hoc announcement 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Evolva Holding SA 
              Duggingerstrasse 23 
              4153 Reinach 
              Switzerland 
Phone:        +41 61 485 20 00 
Internet:     www.evolva.com 
ISIN:         CH0021218067 
Valor:        2121806 
Listed:       SIX Swiss Exchange 
EQS News ID:  1196953 
 
End of Announcement EQS Group News Service 
=------------ 

1196953 17-May-2021 CET/CEST

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1196953&application_name=news 
 

(END) Dow Jones Newswires

May 17, 2021 01:02 ET (05:02 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL 0.21% 35677.02 Delayed Quote.16.33%
EVOLVA HOLDING SA -0.72% 0.137 Delayed Quote.-32.18%
All news about EVOLVA HOLDING SA
09/27EVOLVA : Issues 40 Million New Shares
MT
09/27Evolva issued 40'000'000 shares out of authorized capital
DJ
09/10EVOLVA : HY 2021 Results Presentation (EN)
PU
08/26Evolva Holding Sa Reports Earnings Results for the Half Year Ended June 30, 2021
CI
08/26EVOLVA : Consolidated financial statement HY 2021 (EN)
PU
08/26EVOLVA : Forecasts Return to Profit in Q4 After H1 Operating Loss Doubles
MT
08/26EVOLVA : Half Year Results presentation 2021 (EN)
PU
08/26EQS-ADHOC : Evolva accelerated revenue growth to 60% and expects gross profit to be positi..
DJ
08/26EQS-ADHOC : Evolva accelerated revenue growth to -2-
DJ
05/17EVOLVA : Obtains $22 Million Facility from Nice & Green
MT
More news
Analyst Recommendations on EVOLVA HOLDING SA
More recommendations
Financials
Sales 2021 13,7 M 15,0 M 15,0 M
Net income 2021 -25,1 M -27,4 M -27,4 M
Net cash 2021 4,57 M 4,99 M 4,99 M
P/E ratio 2021 -4,64x
Yield 2021 -
Capitalization 121 M 132 M 132 M
EV / Sales 2021 8,48x
EV / Sales 2022 4,64x
Nbr of Employees 65
Free-Float 84,9%
Chart EVOLVA HOLDING SA
Duration : Period :
Evolva Holding SA Technical Analysis Chart | EVE | CH0021218067 | MarketScreener
Technical analysis trends EVOLVA HOLDING SA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 0,14 CHF
Average target price 0,29 CHF
Spread / Average Target 108%
EPS Revisions
Managers and Directors
Oliver Walker Chief Executive & Financial Officer
Beat In-Albon Chairman
Astrid Schäfer Head-Research & Development
Gerhard Lobmaier Chief Operating Officer
Nic Buergin Secretary, Head-Legal & Compliance
Sector and Competitors
1st jan.Capi. (M$)
EVOLVA HOLDING SA-32.18%132
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455